Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PLEC | Q15149 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL28370603 | 0.83 | IDO1 (0.77) | THRBIDO1KMT2AMEN1KDM4E | |
| SCHEMBL842161 | 0.78 | CHRM2 (0.67) | THRBIDO1KMT2AMEN1KDM4E | |
| SCHEMBL296509 | 0.76 | MAPT (0.56) | THRBIDO1KMT2AMEN1KDM4E | |
| SCHEMBL6895044 | 0.76 | THRB (0.59) | THRBIDO1KMT2AMEN1POLB | |
| SCHEMBL17065246 | 0.76 | THRB (0.59) | THRBIDO1KMT2AMEN1KDM4E | |
| SCHEMBL30183425 | 0.75 | NPC1 (0.50) | IDO1KMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL13853400 | 0.75 | CHRM2 (0.57) | THRBKMT2AMEN1KDM4EHPGD | |
| SCHEMBL9994731 | 0.74 | CHRM2 (0.50) | THRBIDO1KMT2AMEN1KDM4E | |
| SCHEMBL1505831 | 0.74 | MEN1 (0.58) | THRBIDO1KMT2AMEN1KDM4E | |
| SCHEMBL131948 | 0.74 | IDO1 (0.56) | THRBIDO1NOS1NOS2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-4355728-A1 | FRAGRANCE COMPOUNDS | Givaudan SA (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-117500783-A | Perfume compounds | 奇华顿股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116745311-A | Novel antimicrobial peptides having excellent cytoplasmic elution effect of microorganisms | 愢丽科恩株式会社 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022263605-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261956-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2022-12-22 | — | — | WO | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-10954225-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954225-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | US | disclosed |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123482-A2 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | WO | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-6242564-B1 | ADMINISTERING PEPTIDE OF DEFINED AMINO ACID SEQUENCE | ADVANCED IMMUNI T, INC. | 2001-06-05 | — | — | US | disclosed |
| EP-0579363-B1 | Treatment of tropical spastic paresis with peptide T | ADVANCED PEPTIDES & BIOTECH (US) | 2001-01-31 | — | — | EP | disclosed |
| US-5534495-A | ADMINISTERING LINEAR OLIGOPEPTIDE | ADVANCED PEPTIDES AND BIOTECHNOLOGY SCIENCES (US) | 1996-07-09 | — | — | US | disclosed |
| EP-0579363-A1 | Treatment of tropical spastic paresis with peptide T | ADVANCED PEPTIDES AND BIOTECHNOLOGY SCIENCES (US) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | IL5, TSLP, SERPINA6 | THRB 1391/4885IDO1 277/4885KMT2A 4240/4885 |
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | FASN, FAAH2, FADS2 | THRB 3345/4885IDO1 2682/4885KMT2A 2060/4885 |
| US-10954225-B2 | Selective NR2B antagonists | GRIN2B, GRIN2A, GRIN1 | THRB 349/4885IDO1 4175/4885KMT2A 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.